AJANTPHARM — Ajanta Pharma Balance Sheet
0.000.00%
- IN₹304.66bn
- IN₹298.96bn
- IN₹46.48bn
- 98
- 17
- 66
- 68
Annual balance sheet for Ajanta Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 3,782 | 3,282 | 8,401 | 4,595 | 6,138 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8,358 | 10,825 | 11,251 | 13,563 | 12,471 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 20,276 | 22,645 | 28,252 | 27,309 | 28,430 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 16,296 | 16,474 | 16,982 | 17,210 | 18,918 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 37,787 | 40,556 | 46,790 | 46,384 | 50,150 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6,486 | 6,474 | 11,393 | 8,953 | 9,961 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 7,831 | 7,912 | 12,910 | 10,710 | 12,247 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 29,956 | 32,643 | 33,880 | 35,674 | 37,903 |
| Total Liabilities & Shareholders' Equity | 37,787 | 40,556 | 46,790 | 46,384 | 50,150 |
| Total Common Shares Outstanding |